BioAtla, Inc. BCAB 深 滬
已收盤 10-03 16:00:00 美东时间
0.6938
+0.031
+4.69%
華盛通- 最 高0.70
- 今 開0.6668
- 成交量 65.21万股
- 最 低 0.6644
- 昨 收 0.6627
- 總市值 4074.10万
- 52周最高 2.525
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.24
- 委 比 -85.50%
- 總股本 5872.16万
- 歷史最高 76.63
- 量 比 1.05
- 振 幅 5.37%
- 歷史最低 0.24
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioAtla Will Present Clinical Data For Its Investigational Axl-Targeting Antibody-Drug Conjugate Mecbotamab Vedotin At The SITC 2025 Annual Meeting
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of
10-03 21:03
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
BioAtla, Inc. announced that clinical data for its AXL-targeting ADC, mecbotamab vedotin (BA3011), will be presented at the SITC 2025 Annual Meeting. The presentation by Dr. Mihaela Druta of Moffitt Cancer Center on November 7 will highlight a median OS of 21.5 months in 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. The abstract (#523) will be featured in the poster session. BioAtla, ...
10-03 13:00
BioAtla Highlights FDA Alignment On Phase 3 Ozuriftamab Vedotin Trial Design; Says Co Continues Preparations For Enabling Initiation Of Phase 3 Study; Co Maintains Previous Guidance
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3
09-08 20:07
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
BioAtla announced FDA alignment on the Phase 3 design for Ozuriftamab vedotin (Oz-V), including dosing and endpoints for potential accelerated approval. The company plans to initiate the Phase 3 study early next year with a strategic partner. Oz-V, a CAB-ADC targeting ROR2, showed promising results in HPV+ OPSCC with a 45% ORR and 11.6-month median OS in Phase 2 trials. FDA recommends a pivotal trial with 300 patients comparing Oz-V to standard t...
09-08 12:00
JMP Securities Downgrades BioAtla to Market Perform
JMP Securities analyst Reni J. Benjamin downgrades BioAtla (NASDAQ:BCAB) from Market Outperform to Market Perform.
08-13 22:15
跨国药企洞察｜默沙东终止康方2亿美元合作项目，跨国药企如何“优中选优”？
（来源：动脉新医药） 编者按： 全球视野下的跨国药企深度洞察——创新、博弈与中国答卷 在全球医药产业发展的宏大叙事中，跨国药企始终扮演着关键角色——他们...
08-12 08:02
H.C. Wainwright Reaffirms Their Hold Rating on BioAtla (BCAB)
H.C. Wainwright analyst Arthur He CFA maintained a Hold rating on BioAtla today...
08-11 18:18
BioAtla Q2 EPS $(0.32) Misses $(0.29) Estimate
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 9.22 percent. This is a 27.27 percent increase over losses of $(0.44) per share from the same
08-08 04:09
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla reports progress on its clinical programs, including the Phase 1 dose-escalation study of BA3182 (a CAB-EpCAM x CAB-CD3 bispecific T-cell engager) and the Fast Track Designated Ozuriftamab vedotin (Oz-V) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). BA3182 has shown promising tumor reductions and prolonged progression-free intervals, with an expected Phase 1 data readout in the second half ...
08-07 20:05
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
